Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,400 shares, a growth of 110.0% from the October 15th total of 4,000 shares. Based on an average daily volume of 29,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are short sold.

Barinthus Biotherapeutics Stock Down 29.7 %

NASDAQ BRNS traded down $0.41 during trading hours on Friday, hitting $0.97. The company’s stock had a trading volume of 263,301 shares, compared to its average volume of 24,928. The stock has a fifty day moving average of $1.30 and a 200 day moving average of $1.54. The firm has a market capitalization of $38.36 million, a P/E ratio of -0.64 and a beta of -0.59. Barinthus Biotherapeutics has a twelve month low of $0.88 and a twelve month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The firm had revenue of $14.97 million for the quarter. During the same quarter last year, the company posted ($0.37) earnings per share. On average, analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BRNS. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Friday, November 8th. Alliance Global Partners reduced their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Institutional Trading of Barinthus Biotherapeutics

Several hedge funds have recently bought and sold shares of BRNS. Alphabet Inc. acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $2,119,000. Catalina Capital Group LLC acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at $25,000. Ipswich Investment Management Co. Inc. bought a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter worth about $32,000. M&G Plc acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter worth approximately $7,276,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Barinthus Biotherapeutics in the first quarter valued at about $1,292,000. 25.20% of the stock is currently owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.